Study Design. A systematic review of randomized and quasi-randomized controlled trials.
Prolotherapy (also called sclerotherapy) is an injectionbased treatment for chronic musculoskeletal pain. Its proposed mode of action is the reduction of joint instability through the strengthening of stretched or torn ligaments. 1 Its most common application in the back is chronic nonspecific low back pain that has not responded to other therapies. Published treatment protocols vary, but all include the injection of an irritant (proliferant) solution into ligaments and tendinous attachments at weekly or fortnightly intervals for three to eight treatments. [2] [3] [4] [5] Most protocols include one or more co-interventions to enhance the response.
Proponents of prolotherapy believe that ligament injections trigger an influx of granulocytes, macrophages, and fibroblasts, the release of growth factors, and ultimately, collagen deposition, leading to strengthening of ligaments. This may lead to a reduction in pain and disability. Histological studies in both animals and humans demonstrate an increase in mass and thickness of ligaments treated with prolotherapy. 6, 7 Proliferant solutions are classified by their purported actions into irritants, chemotactics, and osmotics. 8 Irritants include phenol, guaiacol, tannic acid, and pumice flour. The sole chemotactic is sodium morrhuate. Osmotic proliferants include concentrated solutions of glucose, glycerin, and zinc sulfate. Local anesthetic (commonly lignocaine) is often added to proliferant solutions to reduce post-injection pain.
Prolotherapy injections are often supplemented by one or more co-interventions. 2, 3, 5, 9 Treatments prior to prolotherapy injections into hypersensitive tender points, infiltration of lumbosacral ligaments with lignocaine, or low back manipulation under intravenous sedation and analgesia. During and after the course of pro-lotherapy injections, co-interventions may include lumbar flexion and extension exercises to induce optimal strengthening of the treated ligaments, regular walking, encouragement to recommence previously painful activities and use of oral vitamin C, and zinc and manganese supplements, ostensibly to facilitate collagen growth.
Given the multiple components of prolotherapy protocols, clinical trials of prolotherapy have variously assessed the efficacy of single components and multiple components concurrently. This systematic review focuses on the efficacy of the core intervention, namely the prolotherapy injections, in reducing pain and disability in chronic low back pain in adults.
Materials and Methods

Criteria for Considering Studies for This Review.
Studies. Both randomized controlled trials (RCTs) and quasi-RCTs (using, for example, birth date to assign participants to groups) comparing prolotherapy injections to control injections or other therapies were included. The use of cointerventions that formed part of established prolotherapy protocols was acceptable.
Nonrandomized controlled studies and noncontrolled experimental studies such as case series or case-control studies were excluded. There were no limits on publication dates of trials or language of publication.
Participants. Studies with participants aged 16 years and older, with a history of nonspecific low back pain of longer than 3 months' duration, were included. Low back pain was defined as pain in the lumbar region, with or without pain in the sacral region, gluteal regions, and radiation to the lower extremities. Exclusion criteria in studies were lumbar/sacral radiculopathies and pathologic causes of back pain.
Interventions. For inclusion, prolotherapy injections had to be administered to at least one group within the trial. Comparison groups could include injections with a control solution or a different therapy not involving injections. For chronic nonspecific low back pain, the prolotherapy solutions are injected into the ligaments and tendons regarded as the sources of the pain. The choice of injection sites is determined either by a standard list of points 3 or by the patterns of pain and tenderness. 9 The skin through which injections are given at each treatment visit is anesthetized with wheals of local anesthetic. Cointerventions used with prolotherapy injections vary with different protocols and are described in the introduction and in Table 1 .
Outcome Measures. The choice of outcomes for inclusion in this systematic review was based on the list recommended by the editorial board of the Cochrane Collaboration Back Review group. 10 As a minimum requirement, studies had to include measures of low back pain and low back-related disability before and after the intervention. [11] [12] [13] [14] [15] The key outcomes used in this review for these measures of pain and disability were the mean (SD) scores and the proportion achieving more than 50% reduction in scores.
Search Strategy for Identification of Studies. All relevant studies meeting our inclusion criteria were identified by: Methods of the Review.
Study Selection. Two reviewers (C.D.M. and S.P) independently applied the inclusion criteria to the titles and abstracts of studies identified through aforementioned search strategies, to select studies for inclusion. There were no disagreements about the eligibility of studies for inclusion.
Methodologic Quality Assessment.
The full text of all studies meeting inclusion criteria was obtained. The methodologic quality of these studies was assessed independently by two reviewers (C.D.M. and S.P), neither of whom were coauthors of the studies. They were blinded to the studies' authors, institutional affiliation, and journal. They rated each study according to the 11 internal validity criteria ( Table 2 ) and methods of operationalization recommended by the Cochrane Collaboration Back Review group. 16 Studies fulfilling six or more of the 11 criteria were considered to be of high quality.
Data Extraction and Analysis. Two reviewers (C.D.M. and S.P) independently extracted the data using a standardized form. For analysis of dichotomous outcome measures, the differences between groups in each study were expressed as the relative risk (RR) with 95% confidence intervals (95% CI). For between-group comparisons of continuous measures, the effect size was estimated as standardized mean differences (SMD) with 95% CI to accommodate the different scales used in each study.
Clinical homogeneity was evaluated by exploring the differences between the RCTs with regard to study population, types of interventions in treatment and control groups, and the types of outcomes. Analysis by statistical pooling was not performed because of the clinical heterogeneity among intervention groups and among control groups. No two studies tested the same component(s) of treatment and had the same number of injection treatments. The results and conclusions were described using a rating system for levels of evidence recommended by the Cochrane Collaboration Back Review Group. 16 
Results
Study Selection
The search strategy identified five studies, four of which were eligible for inclusion in the review.
2-5 The other study was a pilot comparative study with concurrent controls but was excluded as randomization was not used. 17 Contact with content experts revealed one further study submitted for publication. 18 This study was excluded because 20% of its participants had thoracic or cervical spinal pain and the study design involved crossover between experimental and control injections on the second treatment, making long-term results uninterpretable.
Study Characteristics
Study characteristics are presented in Table 1 . The studies eligible for this review were of high quality, meeting at least nine of the 11 internal validity criteria for methodological assessment. 16 In addtion to the exclusion criteria mentioned above, they all excluded patients who had undergone surgery and those whose pain was the subject of unresolved litigation. The protocols for experimental and controls were complex and varied, making intertrial comparisons difficult. No study had a control group that did not receive injections. Within each study, the experimental and control groups received the same protocol of ligament injections, but with different solutions. Ongley et al compared glucose/glycerin/phenol/lignocaine solution with a normal saline control solution.
3 They concurrently compared three co-interventions with respective controls with allocation tied to the injection group, making it impossible to attribute any effect to a single component of the treatment protocol. Klein 2 This study concurrently tested the effect of the exercise cointervention using a factorial design, with independent random allocation of participants to either exercises or normal activity. Effect Measurements. All studies reported mean scores for pain and disability at zero and 6 months ( Table 1 ). All studies, with the exception of Dechow et al, also reported the proportion achieving at least 50% reduction in pain and/or disability scores at 6 months. 4 . Several secondary outcomes, including pain diagram grid scores, physical performance tests, and adverse event rates, were reported but not consistently across studies. Both groups: superficial injections of lignocaine over deep injection points; oral vitamin C, zinc and manganese supplements daily; randomly assigned to 40 flexionextension exercises daily, experimental (n ϭ 28), control (n ϭ 27), or normal activity, experimental (n ϭ 26), control (n ϭ 29) 2. Modified Roland-Morris disability questionnaire: (E) 13.7 (4.9), 7.9 (7.5), 8.0 (7.1) 8.6 (7.5); (C) 14.3 (4.6), 9.3 (5.7), 9.8 (6.5), 9.4 (7. Follow-up periods were 6 months, with the exception of Yelland et al, which followed participants for 24 months. 
Efficacy
The key results for pain and disability are summarized in Table 1 and Figures 1 and 2 . For between-group differences in the proportion of participants showing more than 50% reduction in scores from baseline at 6 months, two studies reported significant differences between the treatment group and the control group (Figure 1) . In Ongley et al, these proportions for disability were 88% and 39%, respectively (RR 2.24, 95% CI 1.50 -3.35, P Ͻ 0.03). 3 In Klein et al, these proportions for both pain and disability were 77% (treatment) and 53% (control) (RR 1.47, 95% CI 1.04 -2.06, P ϭ 0.04). 5 In the study by Yelland et al, these proportions were not significantly different. For pain they were 50% (treatment) and 46% (control) (RR 1.10, 95% CI 0.75-1.61, P ϭ 0.85) and for disability they were 49% (treatment) and 32% (control) (RR 1.50, 95% CI 0.94 -2.40, P ϭ 0.08). 2 No such proportions were reported by Dechow et al. 4 The long-term results of Yelland et al showed a similar pattern.
2 At 12 months, the proportion of participants showing more than 50% reduction in scores from baseline for pain were 46% (treatment) and 36% (control) (RR 1.29, 95% CI 0.81-2.04, P ϭ 0.32) and for disability were 42% (treatment) and 32% (control) (RR 1.31, 95% CI 0.79 -2.16, P ϭ 0.32). At 24 months, the proportion of participants showing more than 50% reduction in scores from baseline for pain were 48% (treatment) and 39% (control) (RR 1.22, 95% CI 0.75-1.97, P ϭ 0.52) and for disability were 48% (treatment) and 35% (control) (RR 1.37, 95% CI 0.82-2.27, P ϭ 0.28).
For between-group differences in the mean pain and disability scores at 6 months, the only study that reported significantly greater reductions in mean pain and disability scores favoring the treatment group was that by Ongley et al 3 ( Figure 2 ). For pain scores, the SMD was Ϫ1.00 (95% CI, Ϫ1.46 to Ϫ0.53, P Ͻ 0.001) and for disability, the SMD was Ϫ0.81 (95% CI, Ϫ1.26 to Ϫ0.35, P Ͻ 0.001). In Klein et al, the difference in these reductions favoring the treatment group was reported as borderline significant. 5 For pain scores, the SMD was Ϫ0.31 (95% CI, Ϫ0.76 to 0.13, P ϭ 0.056) and for disability, the SMD was Ϫ0.09 (95% CI, Ϫ0.53 to 0.35, P ϭ 0.068). Only with exclusion of a subgroup of participants with hypersensitive gluteal tender points, treated with triamcinolone injections on the first day of treatment, did the difference in these reductions achieve statistical significance (P ϭ 0.030 for mean pain and P ϭ 0.016 for mean disability). In Dechow et al, there were no significant differences between groups. 4 For pain scores, the SMD was 0.14 (95% CI, Ϫ0.32 to 0.59, P not reported) and for disability, the SMD was 0.03 (95% CI, Ϫ0.43 to 0.49, P not reported). Similarly, according to Yelland et al, there were no significant differences be- Figure 1 . Between-group differences in the proportion of participants showing more than 50% reduction in pain and disability scores from baseline at 6 months. Summary results are expressed as relative risk (RR) with 95% confidence intervals (95% CI). tween groups. 2 For pain scores, the SMD was Ϫ0.10 (95% CI, Ϫ0.47 to 0.28, P ϭ 0.61) and for disability, the SMD was Ϫ0.22 (95% CI, Ϫ0.59 to 0.16, P ϭ 0.30). Similarly, there were no significant differences between groups in this study at 12 and 24 months.
Changes in secondary outcomes reflected those observed in the primary outcomes with a few notable exceptions. In Ongley et al, there were no differences between groups in clinical signs at 6 months. 3 The improvement in pain diagram grid scores at 6 months in Klein et al was significantly better in the treatment group than in the control group (P ϭ 0.025), 5 but not in the other studies. Significant improvements from baseline occurred in lumbar motion range, isometric strength, and velocity of movement in treatment and control groups in Klein et al, but there were no significant differences between groups. 5 A separate analysis of the exercise co-intervention in Yelland et al reported no differences in pain and disability responses between exercise and normal activity groups at any point in the study. 
Adverse Events
The commonest adverse events reported were temporary increases in back pain and stiffness following injections, reported by nearly all participants at some point in three studies, 2, 3, 5 with only a few reporting increased pain postinjection in the remaining study. 4 Postinjection headaches suggestive of lumbar puncture occurred in 2% in Klein et al 5 and in 4% in Yelland et al. 2 In Ongley et al, there was also a 2% incidence of postmenopausal spotting, attributed to the initial triamcinolone injections. 3 In Yelland et al, 4 participants (4%) developed leg pain with neurologic features, but CT or MRI scanning showed evidence of nerve root compression by herniated discs and/or osteophytes. 2 Three of these resolved with symptomatic treatment and the fourth with a laminectomy. In Yelland et al, there were also reports of nausea/diarrhea in 42%, thoracic spinal pain in 10%, and other symptoms in 56%, but symptoms were generally transient. No study reported any significant differences in the incidence of adverse events between treatment and control groups.
Discussion
Despite an extensive search, only four articles on prolotherapy injections for chronic low back pain were available for review. The quality of all studies was high. The treatment and control group protocols varied from study to study, making meta-analysis impossible. Consequently, the conclusions of this review are based on the results of individual studies.
Given the inconsistent findings among the four studies, this review concludes that there is conflicting evidence regarding the efficacy of prolotherapy injections for the treatment of chronic low back pain. Conclusions are confounded by clinical heterogeneity among studies and by the presence of co-interventions. Two studies that compared prolotherapy injections directly against control injections found no evidence that prolotherapy injections are more effective. 2, 4 One study comparing prolotherapy injections with control injections, in the presence of the same cointerventions, found prolotherapy injections to be more effective in achieving more than 50% reduction in pain or disability, but not for mean pain or disability scores. 5 The remaining study demonstrated that prolotherapy injections with co-interventions are more effective than control injections with control co-interventions. 3 However, this study failed to define the contribution of the prolotherapy injections to the effectiveness of treatment. Further research will be necessary to reconcile these conflicting findings.
The confounding effect of co-interventions raises important questions about the active component(s) of treatment in prolotherapy protocols. Of note were the signifi- Figure 2 . Between-group differences in the mean pain and disability scores at 6 months. Summary results are expressed as standardized mean differences (SMD) with 95% confidence intervals (95% CI).
cant and sustained reductions in pain and disability in both the intervention and control groups of studies with six or more injection treatments with at least 20 mL of solution, in contrast with the lack of response in the study with three injection treatments with 10 mL of solution. This raises the possibility of a dose-response phenomenon with injections in the treatment of chronic low back pain. However, in the absence of a study with randomization to different doses of treatment, it would be improper to conclude that a doseresponse relationship exists.
In all studies, part of the response, in both treatment and control groups, may be attributed to "regression to the mean" and/or the natural history of the back complaint. The phenomenon of regression to the mean results from an increased motivation by people to join trials when their problem is at its worst, making spontaneous improvement more likely. To minimize this effect, at least two of the studies excluded applicants who were experiencing an acute exacerbation of their chronic pain. 2, 3 The natural history of low back pain that is unclear, although evidence from a longitudinal study suggests that the longer the back pain is consistently reported, the more likely it is to persist. 19 The mean duration of pain in the three studies showing sustained improvement in both treatment and control groups exceeded 8 years, making it difficult to attribute much of the observed improvement to natural history. 2, 3, 5 These three studies were also the studies with multiple co-interventions. Co-interventions variously included an initial infiltration of ligaments with local anesthetic followed by manipulation under sedation, superficial skin injections of local anesthetic, the injection of gluteal tender points with triamcinolone/lignocaine, encouragement to perform previously painful activities (activation), vitamin and mineral supplements, and flexionextension exercises. One study specifically examined the effect of the flexion-extension exercises and found they were no more effective than normal activity. 2 The study by Ongley et al, 3 the only one to show a clear difference between treatment and control groups, fails to support the efficacy of prolotherapy injections, because the intervention group differed from the control group in four respects: the premanipulation injections, the manipulation, the muscle tender point injections, and the prolotherapy injections.
In the protocol by Klein et al the glucose/glycerin/ phenol components of the proliferant solution were the only variables between treatment and control groups. 5 With six injection treatments, the prolotherapy group had a statistically significant advantage over the control group in the proportion of participants showing more than 50% reduction in scores from baseline to 6 months. Mean pain and disability scores reduced significantly in both groups over this period, but differences between groups reached significance only if those with hyperirritable gluteal tender points were excluded from the analysis. In contrast, the study by Dechow et al, which used the same components of the injection solution (but with only three injection treatments), showed no reductions in pain and disability from baseline and no differences between groups. 4 Yelland et al evaluated the effects of glucose/lignocaine injections and found they resulted in no greater improvement than saline injections. 2 However, both the prolotherapy and control groups in this study demonstrated significant and sustained reductions in pain and disability scores over a 2-year period.
Collectively, these findings leave many questions unanswered about the efficacy and mechanism of action of prolotherapy injections. Klein et al considered a gradual denervating effect of the phenol component as a possible mechanism of pain relief. 5 Alternatively, the beneficial effect could be attributed to the needles rather than the specific injection solution, by a counterirritation effect. This has been shown elsewhere to inhibit pain in humans. 20 Finally, the original hypothesis that reductions in pain and disability stem from strengthening of ligaments by prolotherapy injections has neither been confirmed nor refuted by the evidence provided by the four studies.
Prolotherapy injections are not without adverse events, with the majority of participants experiencing a transient increase in pain and stiffness and a few percent with severe headaches suggestive of lumbar puncture. However, no serious or permanent adverse events were reported. Patients considering prolotherapy should balance the possibility of transient adverse events against the potential benefits of this therapy.
Conclusion
Implications for Practice
The present studies provide no evidence that prolotherapy injections alone have a beneficial role in the treatment of chronic low back pain. However, repeated ligament injections, irrespective of the solution used, may give prolonged partial relief of pain and disability as part of a multimodal treatment program. Transient increases in pain and stiffness are likely with such treatment, but serious adverse events are unlikely.
Implications for Research
Further experimental and clinical studies are needed to elucidate the effects of prolotherapy injections. These studies should also investigate the specific effects of the most common co-interventions to prolotherapy injections. Further research is needed into the predictors of treatment success, so that it can be better targeted to those who may benefit from it.
There is a need for RCTs comparing prolotherapy with noninjection therapies, as the only available study to date is a nonradomised pilot study. 17 . There is also a need for RCTs on prolotherapy for discogenic back pain confirmed by discography, following promising results from a pilot study of this treatment. 21 
Key Points
• A systematic review of randomized and quasirandomized controlled trials was performed to determine the efficacy of prolotherapy injections in adults with chronic low back pain.
• There was no evidence that prolotherapy injections alone were more effective than control injections alone.
• However, in the presence of co-interventions, prolotherapy injections were more effective than control injections.
